Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Stoke Therapeutics Inc

STOK
Current price
8.29 USD +0.03 USD (+0.36%)
Last closed 8.15 USD
ISIN US86150R1077
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 648 316 096 USD
Yield for 12 month +27.54 %
1Y
3Y
5Y
10Y
15Y
STOK
21.11.2021 - 28.11.2021

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts. Address: 45 Wiggins Avenue, Bedford, MA, United States, 01730

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

22.29 USD

P/E ratio

Dividend Yield

Current Year

+8 780 000 USD

Last Year

+12 405 000 USD

Current Quarter

+4 894 000 USD

Last Quarter

+4 831 000 USD

Current Year

+8 780 000 USD

Last Year

+12 405 000 USD

Current Quarter

+3 783 000 USD

Last Quarter

+3 721 000 USD

Key Figures STOK

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -115 030 000 USD
Operating Margin TTM -613.06 %
Price to Earnings
Return On Assets TTM -27.50 %
PEG Ratio
Return On Equity TTM -52.06 %
Wall Street Target Price 22.29 USD
Revenue TTM 16 743 000 USD
Book Value 4.38 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 47.90 %
Dividend Yield
Gross Profit TTM 12 405 000 USD
Earnings per share -2.11 USD
Diluted Eps TTM -2.11 USD
Most Recent Quarter III 2024
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics STOK

Max Ratio

>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Dividend History STOK

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Ex Dividend Date
Dividend CAGR 3Y
Dividend CAGR 5Y
Dividend CAGR 10Y
Consecutive Years
Consistent Years
Continuous Dividends
Forward Annual Dividend Yield
Forward Annual Dividend – USD
Last Split Factor 1:9
Payout Ratio
Last Split Date 06.06.2019

Stock Valuation STOK

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 24.57
Price Sales TTM 38.72
Enterprise Value EBITDA -3.62
Price Book MRQ 2.79

Financials STOK

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators STOK

For 52 weeks

4.09 USD 17.58 USD
50 Day MA 12.49 USD
Shares Short Prior Month 6 403 252
200 Day MA 12.86 USD
Short Ratio 13.77
Shares Short 6 734 989
Short Percent 18.99 %
Dividend information is being updated